EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterizing Properdin-Inhibited C3 Nephritic Factors in Patients with Complement-Mediated Kidney Diseases

Kes H Stevens iD, Rianne J F Maas, Elena B Volokhina, Erik J M Toonen iD, Nicole C A J van de Kar iD, Lambertus P W J van den Heuvel iD, Marloes A H M Michels iD

International Journal of Molecular Sciences · 29.07.2026 · 27 (15) · 6790

DOI: 10.3390/ijms27156790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.07.2026. Verfasst von Kes H Stevens und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, 6525 Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Properdin, Complement C3 Nephritic Factor, Glomerulonephritis, Membranoproliferative, Complement C3. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being, Nierstichting, Amalia Kinderziekenhuis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) are severe complement-mediated kidney diseases. In a substantial proportion of these patients, C3 nephritic factors (C3NeFs) are detected; these autoantibodies stabilize the complement alternative pathway (AP) C3 convertase. Previous studies have investigated and distinguished properdin-dependent and properdin-independent C3NeFs. In this study, we investigated a distinct subset of C3NeFs that are exclusively active in the absence of properdin: properdin-inhibited C3NeFs. A two-step hemolytic AP convertase activity assay was employed to examine convertase activity in patient serum in the presence versus absence of properdin using the properdin inhibitor Salp20. In 7/16 patients and 1/23 healthy controls, who showed no convertase stabilization in full serum, convertase stabilization was observed upon properdin inhibition, indicating properdin-inhibited C3NeF activity. Consistent findings were obtained when purified patient Igs were added to properdin-depleted serum. Moreover, in an ELISA-based C3bBb binding assay, 6/7 patients with properdin-inhibited C3NeFs showed increased convertase binding, which decreased upon addition of properdin. Complement levels in patients with properdin-inhibited C3NeFs were not significantly different from those in the C3NeF-negative group, and properdin levels were generally within the refence range. In conclusion, our results support the existence of properdin-inhibited C3NeFs, thereby further expanding the functional heterogeneity of these autoantibodies. Although their functional relevance under physiological conditions remains unclear, these findings may have important implications for complement-targeted therapies, particularly strategies aimed at properdin inhibition, as the presence of these C3NeFs may predispose to unintended effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProperdinComplement C3 Nephritic FactorGlomerulonephritis, MembranoproliferativeComplement C3Kidney DiseasesHumansFemaleMaleAutoantibodiesAdultMiddle AgedComplement Pathway, AlternativeComplement C3-C5 Convertases

Stichwörter der Autor:innen

C3 glomerulopathyC3 nephritic factorsSalp20alternative pathwaycomplement systemproperdin

Substanzen

ProperdinComplement C3 Nephritic FactorAutoantibodiesComplement C3Complement C3-C5 Convertases

Autor:innen und Institutionen

  • Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.
  • R&D Department, Hycult Biotech, 5405 Uden, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.
  • Department of Pediatrics/Pediatric Nephrology, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Department of Development and Regeneration, Catholic University Leuven, 3000 Leuven, Belgium.

ORCID-Profile: Kes H Stevens, Erik J M Toonen, Nicole C A J van de Kar, Lambertus P W J van den Heuvel, Marloes A H M Michels

Förderung

  • ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being
  • Nierstichting
  • Amalia Kinderziekenhuis
  • Dutch Kidney Foundation
  • Netherlands Organization for Health Research and Development
  • Sengers Stipendium, Amalia Children’s Hospital, Radboudumc, Nijmegen

Zitieren

APA

Stevens, K. H., Maas, R. J. F., Volokhina, E. B., Toonen, E. J. M., van de Kar, N. C. A. J., van den Heuvel, L. P. W. J., & Michels, M. A. H. M. (2026). Characterizing Properdin-Inhibited C3 Nephritic Factors in Patients with Complement-Mediated Kidney Diseases. International Journal of Molecular Sciences, 27(15), 6790. https://doi.org/10.3390/ijms27156790

Vancouver

Stevens KH, Maas RJF, Volokhina EB, Toonen EJM, van de Kar NCAJ, van den Heuvel LPWJ, et al. Characterizing Properdin-Inhibited C3 Nephritic Factors in Patients with Complement-Mediated Kidney Diseases. International Journal of Molecular Sciences. 2026;27(15):6790. doi:10.3390/ijms27156790

BibTeX
@article{Stevens2026,
  author = {Stevens, Kes H and Maas, Rianne J F and Volokhina, Elena B and Toonen, Erik J M and van de Kar, Nicole C A J and van den Heuvel, Lambertus P W J and Michels, Marloes A H M},
  title = {Characterizing Properdin-Inhibited C3 Nephritic Factors in Patients with Complement-Mediated Kidney Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6790},
  doi = {10.3390/ijms27156790}
}
Kostenlos starten →